SHANGHAI, November 6, 2023 /PRNewswire/ -- At the 6th CIIE, Siemens Healthcare exhibited the world's first four-dimensional volumetric intracardiac ultrasound catheter ACUSON AcuNAV Volume[1](Hereafter referred to as “four-dimensional ICE catheter”). This ultrasound catheter is a pioneering innovative device in the field of structural heart disease, pioneering changes in surgical procedures for ultrasound in structural heart disease.
Siemens Healthcare four-dimensional volumetric intracardiac ultrasound catheter
Today, the world is facing an aging population. Various arrhythmia diseases such as valvular heart disease and atrial fibrillation have become important causes threatening people's health, and the challenges of structural heart disease surgery are becoming more complex and serious. According to forecasts, globally, the number of structural heart disease surgeries in 2030 will triple that of 2020[2]。 Traditional ultrasound can guide structural heart disease interventions in two ways, all of which require a cardiac interventionist and sonographer at the same time. The first is transesophageal echocardiography (“TEE” for short). Patients require total anesthesia. It is not suitable for patients who cannot tolerate total anesthesia and have relative or absolute contraindications to TEE. The second is transthoracic echocardiography (“TTE” for short). The patient's acoustics and ultrasound doctor's skills are high, and it is also relatively difficult to obtain satisfactory cardiac images. With the development of cardiac ultrasound technology, in recent years, intracardiac echocardiography technology has become the main imaging guidance method for treating arrhythmias and structural heart disease due to its advantages of zero radiation and low trauma. Using a four-dimensional ICE catheter to guide the interventional procedure for structural heart disease, the images are clear and comprehensive. Patients do not need full anesthesia, recover quickly after surgery, and do not need additional ultrasound doctors to optimize doctor resources.
The new generation of four-dimensional ICE catheters has a series of breakthrough advantages in the application of interventional procedures for structural heart disease. The catheter is completely controlled by the cardiologist himself to achieve high-definition high-frame-frequency intracardiac volumetric imaging under direct observation, like the doctor's “third eye”. It helps the doctor observe the three-dimensional structure in the heart cavity in real time during surgery, and can detect abnormal blood flow information in a timely manner, guide the doctor to perform interventional treatment such as valve repair, replacement, or left ventricular ear blockage, etc., so that the doctor has no worries, and improves the success rate and efficiency of the operation. During surgery, the four-dimensional ICE catheter can monitor the patient's complications throughout the process, such as the occurrence of blood clots and pericardial effusion. Its high sensitivity helps doctors effectively avoid surgical risks, improve surgical safety, and ensure the patient's health and safety.
Currently, one-tenth of the world's elderly over the age of 75 suffer from moderate to severe tricuspid regurgitation[2]。 Conventional ultrasound catheters were unable to obtain an ideal image of the tricuspid valve, making tricuspid valve repair or replacement surgery more difficult. Today, due to different approaches, the four-dimensional ICE catheter directly enters the right atrium in the heart chamber, enabling doctors to clearly observe the tricuspid valve, solving this “neglected valve” imaging dilemma in a breakthrough way, enabling patients to receive timely diagnosis and treatment, thus helping patients improve their quality of life.
Over the past 20 years, Siemens Healthcare has continued to innovate and accumulate in the field of ultrasound catheters. From the first two-dimensional ICE catheter in 2000 to the new generation of four-dimensional ICE catheters now, more than 2 million ultrasound catheters have been used clinically worldwide. The world's first four-dimensional ICE catheter, ACUSON AcuNaV Volume, is a powerful tool for structural heart disease created by Siemens Healthcare, focusing on doctors and patients, and is expected to become the best guidance tool for interventional procedures for structural heart disease.
[1] The ACUSON AcuNav Volume 4D ICE catheter has received CE marking and FDA approval. |
[2]
|
About Siemens Healthcare
Siemens Healthcare (Frankfurt Stock Exchange: SHL), based in Erlangen, Germany, is a leading medical technology company dedicated to continuously developing a portfolio of products and services, including AI-based applications and digital products that play an increasingly important role in the development of next-generation medical technology. These new applications will further strengthen the company's foundation in the fields of in vitro diagnosis, image-guided treatment, in vivo diagnosis, and novel cancer diagnosis and treatment. At the same time, Siemens Healthcare provides a wide range of services and solutions to help medical service providers improve their capabilities and provide patients with high-quality and efficient services. In fiscal year 2022 (ending September 30, 2022), Siemens Healthcare had total revenue of 21.7 billion euros and approximately 69,500 employees worldwide.
The realm of innovation, for every life! For more information, visit Siemens Healthcare's official website: